Figure 4.
High sIgM expression before therapy associates with residual signaling capacity downstream of BTK during ibrutinib. Residual anti-IgM–induced signaling capacity was measured by flow cytometry (sIgM iCa2+) (A) and immunoblotting (pERK inducibility) (B) in a total of 18 patients with CLL. Levels of sIgM were determined before start of ibrutinib therapy. The statistical difference was calculated using the Mann-Whitney U-test.

High sIgM expression before therapy associates with residual signaling capacity downstream of BTK during ibrutinib. Residual anti-IgM–induced signaling capacity was measured by flow cytometry (sIgM iCa2+) (A) and immunoblotting (pERK inducibility) (B) in a total of 18 patients with CLL. Levels of sIgM were determined before start of ibrutinib therapy. The statistical difference was calculated using the Mann-Whitney U-test.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal